Sotiburafusp alfa

索布瑞芙普α

Report date: 2026/05/20 20:02:01

Base Information

Drug NameSotiburafusp alfa
Drug Alias Nameanti-PD-L1 monoclonal antibody-VEGFR1 fusion protein HB0025HB0025HB-0025
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockersVascular endothelial growth factor inhibitors
TargetsProgrammed death-ligand 1Vascular endothelial growth factor
Therapy Area/IndicationsSolid tumoursKidney NeoplasmsEndometrial Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co LtdZhejiang Huahai Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursKidney NeoplasmsEndometrial Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A